About Daiichi Sankyo
Daiichi Sankyo is a company based in Tokyo (Japan) founded in 2005.. The company has 19,770 employees as of March 31, 2024. Daiichi Sankyo has completed 3 acquisitions, including Ambit Biosciences, Luitpold and Plexxikon. Daiichi Sankyo operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, Merck, Roivant Sciences and BeiGene, among others.
- Headquarter Tokyo, Japan
- Employees 19770 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Daiichi Sankyo Company, Limited
-
Annual Revenue
$12.04 B (USD)17.77as on Mar 31, 2024
-
Net Profit
$1.88 B (USD)47.34as on Mar 31, 2024
-
EBITDA
$2.4 B (USD)50.82as on Mar 31, 2024
-
Latest Funding Round
$236.45 K (USD), Grant
Sep 10, 2021
- Investors
-
Employee Count
19770
as on Mar 31, 2024
-
Investments & Acquisitions
Ambit Biosciences
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Daiichi Sankyo
Daiichi Sankyo is a publicly listed company on the TSE with ticker symbol 4568 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Leadership Team
100 people
Software Development Team
38 people
Data Analysis and Operations Team
20 people
Product Management Team
17 people
Manager Team
16 people
Legal and Compliance
15 people
Sales and Marketing
13 people
Operations Team
9 people
Unlock access to complete
Funding Insights of Daiichi Sankyo
- Total Funding Total Funding
- Total Rounds 1
- Last Round Grant — $236,453
-
First Round
First Round
(10 Sep 2021)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2021 | Amount | Grant - Daiichi Sankyo | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Daiichi Sankyo
Daiichi Sankyo has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include GrandEst. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Access and development services for government programs are provided.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Daiichi Sankyo
Daiichi Sankyo has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Ambit Biosciences, Luitpold and Plexxikon. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Kinase inhibitors for cancer and immune disorders were developed.
|
2000 | ||||
|
Develops small molecule pharmaceuticals for oncology, CNS and autoimmune diseases
|
2000 | ||||
|
Traditional pharma company engaged in development and marketing of variety of pharmaceutical products and medical devices
|
1910 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Daiichi Sankyo
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Daiichi Sankyo Comparisons
Competitors of Daiichi Sankyo
Daiichi Sankyo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, Merck, Roivant Sciences and BeiGene, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Daiichi Sankyo
Frequently Asked Questions about Daiichi Sankyo
When was Daiichi Sankyo founded?
Daiichi Sankyo was founded in 2005 and raised its 1st funding round 16 years after it was founded.
Where is Daiichi Sankyo located?
Daiichi Sankyo is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Who is the current CEO of Daiichi Sankyo?
Sunao Manabe is the current CEO of Daiichi Sankyo.
How many employees does Daiichi Sankyo have?
As of Mar 31, 2024, the latest employee count at Daiichi Sankyo is 19,770.
What is the annual revenue of Daiichi Sankyo?
Annual revenue of Daiichi Sankyo is $12.04B as on Mar 31, 2024.
What does Daiichi Sankyo do?
The company was founded in 2005 and is headquartered in Tokyo, Japan. Operations center on the pharmaceutical sector, where drugs are developed for oncology, cardiovascular conditions, migraine, diabetes, and other therapeutic areas. Enhertu, a HER2-directed antibody-drug conjugate, is provided for breast cancer treatment. Additional products target various unmet medical requirements globally.
Who are the top competitors of Daiichi Sankyo?
Daiichi Sankyo's top competitors include Merck, Moderna and Roivant Sciences.
Is Daiichi Sankyo publicly traded?
Yes, Daiichi Sankyo is publicly traded on TSE under the ticker symbol 4568.
How many acquisitions has Daiichi Sankyo made?
Daiichi Sankyo has made 3 acquisitions, including Ambit Biosciences, Luitpold, and Plexxikon.
Who are Daiichi Sankyo's investors?
Daiichi Sankyo has 1 investor. Key investors include GrandEst.
What is Daiichi Sankyo's ticker symbol?
The ticker symbol of Daiichi Sankyo is 4568 on TSE.